Last reviewed · How we verify
Denosumab-Ref
Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), preventing osteoclast formation and bone resorption.
Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), preventing osteoclast formation and bone resorption. Used for Prevention of skeletal-related events in patients with bone metastases from solid tumors, Treatment of osteoporosis in postmenopausal women and men at high risk of fracture.
At a glance
| Generic name | Denosumab-Ref |
|---|---|
| Also known as | Prolia |
| Sponsor | Lambda Therapeutic Research Ltd. |
| Drug class | RANKL inhibitor (monoclonal antibody) |
| Target | RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Bone Metabolism |
| Phase | Phase 3 |
Mechanism of action
Denosumab binds to RANKL, a key mediator of osteoclast differentiation and activation. By blocking the RANKL-RANK interaction, it reduces bone turnover and increases bone mineral density. This mechanism makes it effective for conditions characterized by excessive bone loss, such as osteoporosis and bone metastases.
Approved indications
- Prevention of skeletal-related events in patients with bone metastases from solid tumors
- Treatment of osteoporosis in postmenopausal women and men at high risk of fracture
Common side effects
- Hypocalcemia
- Osteonecrosis of the jaw
- Atypical femoral fractures
- Infections
- Back pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Denosumab-Ref CI brief — competitive landscape report
- Denosumab-Ref updates RSS · CI watch RSS
- Lambda Therapeutic Research Ltd. portfolio CI